COMMUNIQUÉS West-GlobeNewswire

Philips extends leadership in virtually helium-free MRI with more than 1,000 systems installed, expanding patient access worldwide
28/02/2024
February 28, 2024 At #ECR2024, company also debuting Europe’s first mobile virtually helium-free MRI system Amsterdam, the Netherlands and Vienna, Austria – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in [...]
Nexstim Receives NBS System 5 Order from Neurosurgery Customer in Germany
28/02/2024
Press release, Helsinki, 28 February 2024 at 9 AM (EET) Nexstim Receives NBS System 5 Order from Neurosurgery Customer in Germany Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System [...]
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases
28/02/2024
Unique proprietary non-viral gene therapy platform with minimally invasive delivery technology providing long lasting gene expression and favorable distribution in the retina. Focus on age-related macular degeneration ( [...]
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
28/02/2024
Press Release Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO More than 25 years of experience in senior business development and corporate roles, with over 6 years as Chief Business Officer of Nicox [...]
Gavin Spencer, dirigeant expérimenté du secteur de la biotechnologie, nommé Directeur Général de Nicox
28/02/2024
Communiqué de presse Gavin Spencer, dirigeant expérimenté du secteur de la biotechnologie, nommé Directeur Général de Nicox Plus de 25 ans d'expérience dans des fonctions stratégiques et de Business Development de [...]
Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial
28/02/2024
Press Release Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial Agreement in principle for an amendment to debt agreements for outstanding bonds [...]
Nicox restructure sa dette et réduit sa structure pour étendre son horizon de trésorerie et prioriser les ressources sur l’étude pivotale sur le NCX 470
28/02/2024
Communiqué de presse Nicox restructure sa dette et réduit sa structure pour étendre son horizon de trésorerie et prioriser les ressources sur l’étude pivotale sur le NCX 470 Signature d'un accord de principe pour [...]
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
28/02/2024
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today [...]
Charlotte Hanneman to succeed Abhijit Bhattacharya as Philips’ Chief Financial Officer (CFO)
28/02/2024
February 28, 2024 Proposal to appoint Ms. Hanneman as member of Philips’ Board of Management fulfilling the role of CFO per October 1, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global [...]
Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024
28/02/2024
Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6 th 2024 Ghent, Belgium – 28 February 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the [...]
Idorsia and Viatris enter into a significant global research and development collaboration
28/02/2024
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod. Idorsia to receive an upfront payment of [...]
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
28/02/2024
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, [...]
Cytokinetics Reports Fourth Quarter 2023 Financial Results
27/02/2024
Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints Company Plans to Submit [...]
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
27/02/2024
Conference Call to Begin Today at 5:00 p.m. (ET) 2023 Total revenues of $199M; +99% vs. 2022 4Q 2023 Total revenues of $58M; +62% vs. 2022 4Q 2023 Net income of $1M; Non-GAAP net income of $7M $302M of cash and cash [...]
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
27/02/2024
Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
27/02/2024
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Capital Increase in Genmab as a Result of Employee Warrant Exercise
27/02/2024
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected [...]
Aclarion Announces Closing of $3.0 Million Public Offering
27/02/2024
BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary [...]
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
27/02/2024
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the [...]

Pages